Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC

Clinical trial NCT06876844 · RECRUITING

Trial details

NCT number: NCT06876844
Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Head and Neck Cancer Head and Neck Cancer Squamous Cell Carcinoma

Start date: 2024-12-30
Primary completion: 2027-09-30
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.